Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Accumulated Expenses: 2020-2024

Historic Accumulated Expenses for Foghorn Therapeutics (FHTX) over the last 5 years, with Dec 2024 value amounting to $8.5 million.

  • Foghorn Therapeutics' Accumulated Expenses fell 12.45% to $9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year decrease of 12.45%. This contributed to the annual value of $8.5 million for FY2024, which is 6.34% down from last year.
  • According to the latest figures from FY2024, Foghorn Therapeutics' Accumulated Expenses is $8.5 million, which was down 6.34% from $9.1 million recorded in FY2023.
  • In the past 5 years, Foghorn Therapeutics' Accumulated Expenses ranged from a high of $11.0 million in FY2022 and a low of $8.5 million during FY2024.
  • In the last 3 years, Foghorn Therapeutics' Accumulated Expenses had a median value of $9.1 million in 2023 and averaged $9.5 million.
  • As far as peak fluctuations go, Foghorn Therapeutics' Accumulated Expenses increased by 15.05% in 2022, and later decreased by 17.21% in 2023.
  • Over the past 5 years, Foghorn Therapeutics' Accumulated Expenses (Yearly) stood at $9.2 million in 2020, then increased by 4.38% to $9.6 million in 2021, then grew by 15.05% to $11.0 million in 2022, then declined by 17.21% to $9.1 million in 2023, then dropped by 6.34% to $8.5 million in 2024.